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Vascular endothelial growth factor (VEGF) family mem-
bers and their receptors have long been considered
suitable anticancer targets (1) because of their role in
angiogenesis. Although their full potential remains to
be realized, two monoclonal antibodies have been
Food and Drug Administration-approved against
human cancer: bevacizumab (humanized anti-VEGFA)
and ramucirumab (fully human anti-VEGFR2). In PNAS,
Wentink et al. (2) describe the rational engineering of
3D-structured peptides that mimic the bevacizumab
binding site of VEGFA, thereby eliciting a strong immu-
nogenic response in rats. The resulting sera proved at
least as efficient as bevacizumab itself in inhibiting tu-
mor xenografts in immunodeficient mice. Active immu-
nization of immunocompetent mice bearing syngeneic
tumors was somewhat effective, but limited by: (i) high
mortality upon serial epitope administrations, presum-
ably from anaphylaxis; (ii) need of repeated vaccina-
tions and incomplete tumor control; and (iii) increased
serum VEGF levels. These results raise corresponding
concerns: (i) the anaphylactic response seems related
to the epitope itself, which casts doubt for translational
applications; (ii) it is unlikely that a sufficient response
could be reached in humans to effectively control tu-
mor growth; and (iii) the presence of antibody:VEGF
complexes with decreased clearance rate has to be
discriminated from an actual increase in free VEGF,
which could impact on tumor angiogenesis/metastasis.
Despite such technical limitations, which are
inherent in an initial report, the Wentink et al.
study (2) provides interesting insights. It is well-known
that tumors induce an immunosuppressive microen-
vironment by influencing tumor infiltration by den-
dritic cells and T-regulatory cells (3), a phenomenon
mediated —at least in part—by VEGF family mem-
bers (4). Therefore, a therapeutic approach targeted
to VEGFA would likely contribute to release such im-
munosuppression, besides interferingwith pathological
angiogenesis. Interestingly, a comparable release of
tumor immunosuppression has been observed in
rare cases of spontaneous cancer regression that oc-
cur following surgical removal of the primary tumor,
radiofrequency ablation, and ionizing radiation-based
treatments. Self-vaccination against tumor epitopes
has been invoked as a possible explanation for such
abscopal effect, which has long been recognized in
metastatic renal cell carcinoma (RCC), among a few
other tumor types (5).
In this context, we have designed an antibody fin-
gerprinting technology to identify tumor-directed an-
tibodies in sera from patients. Such a high-throughput
approach proved effective in the identification of
autoantibody signatures in prostate and ovarian
cancer (6–8). In ongoing work, we have applied this
protocol to sera from an index patient with well-
documented spontaneously regressed metastatic
RCC (9), as well as to a classic experimental rat
model of RCC (10), corroborating the presence of
a humoral immunity against the broad repertoire of
tumor vascular antigens. Because Wentink et al. (2)
show that an immune response against VEGFA can
induce preclinical antitumor vaccination, we be-
lieve that a patient-tailored version of this approach
(including other members of the VEGF ligand-
receptor family) could potentially be used to boost
an acquired immune response to strike the tumor.
Thus, evaluation of autoantibody pools against
endothelial epitope combinations to potentially
achieve a comprehensive immune effect would be a
logical preliminary step. Together, these findings
may provide the basis for translation applications
of Wentink et al. (2).
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